The authors make no claims of the accuracy of the information contained
herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this document shall be liable for any special,
consequential, or exemplary damages resulting in whole or part from any
user's use of or reliance upon this material. PLEASE
READ THE DISCLAIMER CAREFULLY BEFORE
ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE
TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
Standard Dilutions [Amount of drug]
[Infusion volume] [Infusion rate]
[0 to 35 mcg] [50 ml] [15 - 30min]
Stability / Miscellaneous
Store refrigerated 2° to 8°C (36° to 46°F).
Preserve in tight
containers, protected from light.
05 07 15
Supplied: 4 mcg/ml-1 ml
(increases factor VIII levels): 0.3 mcg/kg in 50ml normal saline over
Diabetes insipidus: 2-4 mcg/day IV push or SC.
Decrease bleeding following cardiac bypass: 0.3 mcg/kg ivpb.
Provide short term protection for uremic hemorrhagic tendency: 0.3
mcg/kg ivpb q8h x 2 doses (diminishing response).
Greatly enhanced ADH activity. Less vasopressor activity. Longer DOA.
(Synthetic analog of vasopressin-posterior pituitary hormone).
When Desmopressin Acetate Injection is administered to patients who do
not have need of antidiuretic hormone for its antidiuretic effect, in
particular in pediatric and geriatric patients, fluid intake should be
adjusted downward to decrease the potential occurrence of water
intoxication and hyponatremia with accompanying signs and symptoms
(headache, nausea/vomiting, decreased serum sodium and weight gain).
Particular attention should be paid to the possibility of the rare
occurrence of an extreme decrease in plasma osmolality that may result
in seizures which could lead to coma.
Desmopressin acetate should not be used to treat patients with Type IIB
von Willebrand’s disease since platelet aggregation may be induced.
DOSAGE AND ADMINISTRATION
Hemophilia A and von Willebrand's Disease (Type I): Desmopressin
Acetate Injection 4 mcg/mL is administered as an intravenous infusion
at a dose of 0.3 mcg desmopressin acetate/kg body weight diluted in
sterile physiological saline and infused slowly over 15 to 30 minutes.
In adults and children weighing more than 10 kg, 50 mL of diluent is
recommended; in children weighing 10 kg or less, 10 mL of diluent is
recommended. Blood pressure and pulse should be monitored during
infusion. If Desmopressin Acetate Injection 4 mcg/mL is used
preoperatively, it should be administered 30 minutes prior to the
The necessity for repeat administration of desmopressin acetate or use
of any blood products for hemostasis should be determined by laboratory
response as well as the clinical condition of the patient. The tendency
toward tachyphylaxis (lessening of response) with repeated
administration given more frequently than every 48 hours should be
considered in treating each patient.
Diabetes Insipidus: This formulation is administered subcutaneously or
by direct intravenous injection. Desmopressin Acetate Injection 4 mcg/mL
dosage must be determined for each patient and adjusted according to
the pattern of response. Response should be estimated by two
parameters: adequate duration of sleep and adequate, not excessive,
The usual dosage range in adults is 0.5 mL (2 mcg) to 1 mL (4 mcg)
daily, administered intravenously or subcutaneously, usually in two
divided doses. The morning and evening doses should be separately
adjusted for an adequate diurnal rhythm of water turnover. For patients
who have been controlled on intranasal desmopressin acetate and who
must be switched to the injection form, either because of poor
intranasal absorption or because of the need for surgery, the
comparable antidiuretic dose of the injection is about one-tenth the
Parenteral drug products should be inspected visually for particulate
matter and discoloration prior to administration whenever solution and
Desmopressin Acetate Injection 4 mcg/mL is available as a clear
colorless sterile solution as follows:
Ampul - 4 mcg/mL - 1 mL - 10 per Box
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.